🇺🇸 FDA
Patent

US 10166299

AAV mediated aquaporin gene transfer to treat Sjogren's syndrome

granted A61KA61K38/177A61K48/00

Quick answer

US patent 10166299 (AAV mediated aquaporin gene transfer to treat Sjogren's syndrome) held by THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
Grant date
Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/177, A61K48/00, A61K48/005